Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 19/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12913227 | 0.90 | NR1H2 (0.37) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL935102 | 0.89 | NR1H2 (0.38) | NR1H2NR1H3 | |
| SCHEMBL16369355 | 0.88 | NR1H2 (0.38) | NR1H2NR1H3 | |
| SCHEMBL936246 | 0.88 | NR1H2 (0.37) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL12913264 | 0.87 | NR1H2 (0.38) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL16369357 | 0.87 | NR1H2 (0.37) | NR1H2NR1H3 | |
| SCHEMBL935830 | 0.86 | NR1H2 (0.46) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL935863 | 0.84 | NR1H2 (0.32) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL949376 | 0.82 | ALDH1A1 (0.39) | NR1H2NR1H3 | |
| SCHEMBL935861 | 0.81 | NR1H2 (0.32) | NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-9604975-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20150099736-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD (GB) | 2015-04-09 | — | — | US | disclosed |
| US-8916591-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2014-12-23 | — | — | US | disclosed |
| WO-2011010083-A1 | INDOLYL-PYRIDONE DERIVATIVES | VERNALIS (R & D) LTD (GB) | 2011-01-27 | — | — | WO | disclosed |
| WO-2009093012-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | NR1H2 2548/4885NR1H3 2470/4885CA12 4128/4885 |
| US-20150099736-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | NR1H2 2548/4885NR1H3 2470/4885CA12 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.